Can-Fite BioPharma Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Can-Fite BioPharma de winst en omzet met respectievelijk 47.7% en 67.2% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 171.4% per jaar.

Belangrijke informatie

47.7%

Groei van de winst

171.4%

Groei van de winst per aandeel

Biotechs winstgroei	49.5%
Inkomstengroei	67.2%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	12 Nov 2024

Recente toekomstige groei-updates

Recent updates

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19

Winst- en omzetgroeiprognoses

TASE:CANF - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	0	-8	20	-9	2
12/31/2025	14	4	21	21	3
12/31/2024	1	-8	-9	-9	3
6/30/2024	1	-7	-7	-7	N/A
3/31/2024	1	-7	N/A	N/A	N/A
12/31/2023	1	-8	-8	-8	N/A
9/30/2023	1	-9	N/A	N/A	N/A
6/30/2023	1	-10	-10	-10	N/A
3/31/2023	1	-10	N/A	N/A	N/A
12/31/2022	1	-10	-11	-11	N/A
9/30/2022	1	-14	N/A	N/A	N/A
6/30/2022	1	-15	-12	-12	N/A
3/31/2022	1	-16	N/A	N/A	N/A
12/31/2021	1	-15	-10	-10	N/A
9/30/2021	1	-12	N/A	N/A	N/A
6/30/2021	1	-11	-7	-7	N/A
3/31/2021	1	-12	N/A	N/A	N/A
12/31/2020	1	-15	-12	-12	N/A
9/30/2020	1	-13	N/A	N/A	N/A
6/30/2020	2	-17	-14	-14	N/A
3/31/2020	2	-13	N/A	N/A	N/A
12/31/2019	2	-13	-11	-11	N/A
9/30/2019	2	-11	N/A	N/A	N/A
6/30/2019	4	-8	-8	-8	N/A
3/31/2019	3	-7	N/A	N/A	N/A
12/31/2018	4	-7	-4	-4	N/A
9/30/2018	4	-5	N/A	N/A	N/A
6/30/2018	2	-6	-5	-5	N/A
3/31/2018	1	-5	N/A	N/A	N/A
12/31/2017	1	-6	N/A	-9	N/A
9/30/2017	1	-6	N/A	N/A	N/A
6/30/2017	0	-9	N/A	-9	N/A
3/31/2017	0	-7	N/A	N/A	N/A
12/31/2016	0	-8	N/A	-9	N/A
9/30/2016	0	-5	N/A	N/A	N/A
6/30/2016	0	-6	N/A	-8	N/A
3/31/2016	0	-6	N/A	N/A	N/A
12/31/2015	0	-6	N/A	-5	N/A
9/30/2015	0	-7	N/A	N/A	N/A
6/30/2015	0	-5	N/A	-5	N/A
3/31/2015	N/A	-5	N/A	N/A	N/A
12/31/2014	N/A	-6	N/A	-7	N/A
9/30/2014	N/A	-7	N/A	N/A	N/A
6/30/2014	N/A	-8	N/A	-9	N/A
3/31/2014	N/A	-8	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CANF de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CANF de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CANF de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CANF ( 67.2% per jaar) zal naar verwachting sneller groeien dan de markt IL ( 2% per jaar).

Hoge groei-inkomsten: De omzet van CANF ( 67.2% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CANF naar verwachting over 3 jaar hoog zal zijn

Can-Fite BioPharma Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2023

No longer forecast to breakeven

Recent updates

Can-Fite BioPharma Ltd. Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite BioPharma Ltd.'s Partner Vetbiolix Reports Positive Results in Dog Osteoarthritis Study with Piclidenoson

Can-Fite BioPharma Ltd. Receives Approval from Israeli Ministry of Health to Conduct Phase IIa Clinical Trial with Orally-Administered Namodenoson in Treatment of Pancreatic Carcinoma

New major risk - Shareholder dilution

Insufficient new directors

First half 2024 earnings released: US$0.002 loss per share (vs US$0.004 loss in 1H 2023)

Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix

Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study

Can-Fite BioPharma Ltd., Annual General Meeting, Jun 26, 2024

New minor risk - Share price stability

Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022)

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Financial data availability

First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022)

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022)

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Insufficient new directors

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021)

Forecast to breakeven in 2023

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021)

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Insufficient new directors

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate

Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022

We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans

Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat